AI assistant
Alzamend Neuro, Inc. — Director's Dealing 2021
Jun 15, 2021
35321_dirs_2021-06-14_8a48a2f3-d523-4bc9-bf28-0f51aa9a9aec.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Alzamend Neuro, Inc. (ALZN)
CIK: 0001677077
Period of Report: 2021-06-14
Reporting Person: CRAGUN KENNETH S (N/A)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $1.00 | 2028-12-14 | Common Stock (1500000) | Direct | |
| Stock Options (Right to Buy) | $1.50 | 2029-11-17 | Common Stock (1000000) | Direct |
Footnotes
F1: Mr. Cragun was granted stock options to purchase 1,500,000 shares of the Issuer's Common Stock, which options vest ratably over four (4) years beginning on December 15, 2018. The options are exercisable for a period of ten years at an exercise price of $1.50 per share. Of these options, 968,750 shares of Common Stock are currently vested and exercisable.
F2: Mr. Cragun was granted performance-based stock options to purchase 1,000,000 shares of the Issuer's Common Stock, which options are exercisable for a period of ten (10) years at an exercise price of $1.50 per share. Of these options, no shares of Common Stock are currently vested and exercisable.